Inhibition of bone healing by pamidronate in calvarial bony defects

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 103, Issue 3, 2007, Pages 321-328

  Choi, Je Yong ^a   Kim, Hyung Jong ^b   Lee, Yong Chan ^b   Cho, Byoung Ouck ^b   Seong, Ha Soo ^c   Cho, Michael ^d   Kim, Seong Gon ^b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; LACTIC ACID; PAMIDRONIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL; ARTICLE; BIODEGRADABLE IMPLANT; BONE DENSITY; BONE NECROSIS; BONE REGENERATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRONTAL BONE; RABBIT; VASCULARIZATION;

ABSORBABLE IMPLANTS; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; DIPHOSPHONATES; FRONTAL BONE; LACTIC ACID; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEONECROSIS; POLYGLYCOLIC ACID; POLYMERS; RABBITS;

EID: 33847134717     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2006.06.057     Document Type: Article

References (24)

1. Dunford J.E., Thomspson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl disphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 296 (2001) 235-242
2. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci U S A 96 (1999) 133-138
3. Luckman S.P., Co F.P., Ebetino F.H., Russell R.G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational isoprenylation of GTP-binding proteins. J Bone Miner Res 13 (1998) 581-589
4. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255 (1999) 491-494
5. Fleisch H., Reszka A., Rodan G., and Rogers M. Bisphosphonates: mechanisms of action. In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of bone biology (2002), Academic Press, San Diego, CA 1361-1385
6. Rodan G.A., and Reszka A.A. Bisphophonate mechanism of action. Curr Mol Med 2 (2002) 571-577
7. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60 (2000) 6001-6007
8. van Offel J.F., Schuerwegh A.J., Bridts C.H., Stevens W.J., and de Clerck L.S. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61 (2002) 925-928
9. Marx R.E. Pamidronate (Aredia) and oledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
10. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
11. Bagan J.V., Jimenez Y., Murillo J., Hernandez S., Poveda R., Sanchis J.M., et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42 (2006) 327-329
12. Starck W.J., and Epker B.N. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10 (1995) 74-78
13. Heikkila P., Teronen O., Moilanen M., Konttinen Y.T., Hanemaaijer R., Laitinen M., et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloproteinase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13 (2002) 245-254
14. Frame J.W. A convenient animal model for testing bone substitute materials. J Oral Surg 38 (1980) 176-180
15. Grossman S.A., Reinhard C., Colvin O.M., Chasin M., Brundrett R., Tarmago R.J., et al. The intracranial distribution of BCNU delivered by surgically implantable biodegradable polymers. J Neurosurg 76 (1992) 640-647
16. Sparidans R.W., den Hartigh J., Cremers S., Beijnen J.H., and Vermeij P. Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. J Chromatogr B Biomed Sci Appl 730 (1999) 95-99
17. Sim B.K., O'Reilly M.S., Liang H., Fortier A.H., He W., Madsen J.W., et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57 (1997) 1329-1334
18. 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11 (1973) 196-214
19. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 (1995) 1478-1487
20. Abildgaard N., Rungby J., Glerup H., Brixen K., Kassem M., Brincker H., et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 61 (1998) 128-134
21. D'Aoust P., McCulloch C.A., Tenenbaum H.C., and Lekic P.C. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res 302 (2000) 353-363
22. Rodan G., and Fleisch H.A. Bisphosphonates: mechanism of action. J Clin Invest 97 (1996) 2692-2696
23. Zizic T.M., Marcoux C., Hungerford D.S., Dansereau J.V., and Stevens M.B. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 79 (1985) 596-604
24. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538-6544